Background: Fluorouracil-based adjuvant chemotherapy in gastric cancer has been reported to be effective by several meta-analyses. Perioperative chemotherapy in locally advanced resectable gastric cancer (RGC) has been reported improving survival by two large randomized trials and recent meta-analyses but the role of neoadjuvant chemotherapy and optimal regimen remains to be determined. We compared a neoadjuvant with adjuvant docetaxel-based regimen in a prospective randomized phase III trial, of which we present the 10-year follow-up data.
introduction Several meta-analyses reported a minimal benefit for adjuvant 5-fluorouracil (5-FU)-based chemotherapy in gastric cancer compared with surgery alone [1] [2] [3] [4] [5] [6] [7] even though no western large randomized trials showed a significant advantage for a specific intravenous regimen [8] [9] [10] . While in Eastern countries, the oral S-1 and the capecitabine/oxaliplatin combination showed a statistically significant survival benefit after radical gastrectomy [11, 12] , in United States, adjuvant chemoradiation was effective in terms of survival in less than D1-resection [13] . In Europe, two, British and French, large randomized trials reported a significant survival improvement for perioperative epirubicin/cisplatin/5-FU (ECF) and cisplatin/5-FU (CF), respectively, compared with surgery alone in resectable gastric cancer (RGC) [14, 15] . Docetaxel (Taxotere®) was approved in Western countries for metastatic gastric cancer [16] combined with cisplatin and protracted continuous infusion (PVI) 5-FU (DCF). We conducted a phase III trial comparing neoadjuvant versus adjuvant docetaxel/cisplatin/5-FU (TCF) in RGC, which was prematurely stopped due to slow accrual. The results about feasibility and surgical morbidity/mortality were previously published [17] . Here we report the 10-year follow-up data [18] .
patients and methods patient selection and treatment
The study involved chemotherapy-naïve patients with histologically confirmed RGC (T 3-4 Nx M0 or T x N + M0 as defined in the 1997 TNM staging system), WHO performance status of ≤2, age 18-75 years, adequate blood counts, normal renal and liver function, grade ≤2 peripheral neuropathy, and no distant metastases. Siewert type I carcinoma of the oesophago-gastric junction was an exclusion criterion. Patients with positive peritoneal lavage cytology were enrolled provided that macroscopic peritoneal carcinomatosis had been ruled out by laparoscopy. The trial was approved by the Ethics Committees of the participating centres; all patients gave their written informed consent.
The patients were randomized before treatment and stratified by centre, tumour site (Siewert II and III cardia carcinomas versus tumours of the rest of the stomach), and node status (N+ versus N−).
The treatment consisted of 21-day cycles of TCF: a 1-h i.v. infusion of docetaxel 85 mg/m 2 (initially) on day 1, a 4-h i.v. infusion of cisplatin 75 mg/m 2 on day 1, and continuous i.v. infusions of 5-FU 300 mg/m 2 /day on days 1-14. The protocol was amended with a dose of 75 mg/m 2 docetaxel (11 patients in arm A and 7 in arm B) on the basis of previous evidence of a high incidence of febrile neutropenia in metastatic settings [19] . The same chemotherapy was to be administered pre-or postoperatively depending on the randomization into treatment arms. Just before starting chemotherapy, all patients underwent the thoracic placement of a totally implanted central venous catheter (Port-a-cath). For details about supportive care and dose reduction criteria, see supplementary Appendix, available at Annals of Oncology online.
surgery
This was reported in detail in a previous publication [17] .
evaluations before, during, and after trial treatment toxicity and quality-of-life assessments Toxicities were assessed using the National Cancer Institute of CanadaClinical Trials Group (NCIC-CTG, version 3.0) expanded common toxicity criteria.
All patients were asked to complete a quality-of-life (QoL) questionnaire before randomization/before surgery, during TCF treatment, and three times during follow-up. For details, see the supplementary Appendix, available at Annals of Oncology online.
statistical analysis
The primary end point of the trial was event-free survival (EFS), defined as time to relapse, progression, or death due to any cause, starting from randomization. The secondary end points were overall survival (OS), the time-to-treatment failure, toxicity, the rate of complete resection (R0), postoperative mortality, tumour down-staging (baseline endoscopic ultrasound (EUS) versus surgical pathology, according to the AJCC TNM classification, fifth edition), pathological response, QoL, operability after chemotherapy in arm A, and feasibility of chemotherapy after surgery in arm B.
To detect a 15% difference (35% in arm A and 20% in arm B) in EFS at 3 years with a type I error of 5% and a power of 80%, 185 events were required. Taking into account the potential accrual rate and feasibility consideration, the target sample size was set at 240. Time-to-event end points were estimated using the Kaplan-Meier method.
Differences in median number of cycles and median dose intensities between treatment arms were compared using two-sided Wilcoxon tests. An exploratory QoL analysis without adjustment for multiple testing was made as the sample size was much smaller than planned. All scales were linearly transformed to have a range from 0 to 100, with higher values indicating a better condition. The mean changes of QL scores during treatment from the baseline were compared between treatment arms using paired t-tests with a mean change of ≥8 points considered as clinically meaningful [20] .
results patient characteristics
Between December 1999 and August 2005, a total of 70 patients were enrolled by nine institutions in four countries; 85% of the patients were enrolled by two institutions (Milan and Geneva). One patient withdrew consent and did not receive any trial chemotherapy. Thirty-four patients were randomized to arm A and 35 to arm B. One patient in arm A, who died of cancer before therapy could be started, was included in the analyses in accordance with the intention-totreat principle but was not evaluable for toxicity or tolerance (Figure 1) .
The two groups were well balanced (Table 1) . Baseline EUS showed that most of the patients were T3 (75%) (AJCC TNM classification, 5th edition). Siewert II-III tumours represented around one-fourth. A discrepancy in node status detection was observed between computed tomography scan and EUS in arm A.
A number of cycles per patient are reported in Table 2 . Twelve patients in arm B did not receive any trial chemotherapy cycles because of the presence of metastases at laparotomy (three cases), surgical complications [2] , physician's decision [4] , and patient refusal [3] . The medical decisions were based on the early pathological stage in all four cases. toxicity and safety
All dose reductions were due to toxicity; diarrhoea was the most common reason in both arms, and grade 3-4 nausea/vomiting was much more frequent in arm B. Therefore, 5-FU and cisplatin dose reductions were more frequent in arm B than in arm A, whereas docetaxel dose reduction was similar in both groups (Table 2) . There were no between-arm differences in haematological or non-haematological toxicities (supplementary Table S3 , available at Annals of Oncology online).
There were 33 SAEs in 28 patients. Of these events, 24 happened on chemotherapy, 5 on other (1 was postoperative before chemotherapy, 1 was just after inclusion before chemotherapy and 3 during post-surgery period), and four in the follow-up. Two SAEs (6%) were definitely related to trial treatment. Three SAEs (9%) led to temporary or permanent discontinuation of treatment. PS, performance status; TCF, docetaxel-cisplatin-5-fluorouracil; X, the largest diameter of the tumor in the horizontal plane; Y, the largest diameter orthogonal to X. A supportive analysis for the primary end point based on the per-protocol population excluding 12 patients who did not receive any chemotherapy yielded similar results to the intention-to-treat analysis. EFS at 5 years was 44.1% (95% CI 27.3% to 59.7%) in arm A versus 43.5% (95% CI 26.5% to 59.4%) in arm B, and at 10 years 44.1% (95% CI 27.3% to 59.7%) in arm A versus 29.4% (95% CI 14.7% to 45.8%) in arm B (Figure 2A ).
The median OS was 4.3 years (95% CI 2.5-NC) in arm A versus 3.7 years (95% CI 1.6-NC) in arm B; P = 0.5 ( Figure 2B ). OS at 5 years was 47% in arm A versus 46% in arm B and at 10 years 44% in arm A versus 36% in arm B.
surgery
Ninety percent of the patients as a whole underwent D2 or more nodal dissection. Surgical treatment details were object of a previous publication [17] .
quality of life
See supplementary Appendix, available at Annals of Oncology online.
discussion
Provided that our study is underpowered due to the early interruption, no statistically significant difference was observed for the primary end point, EFS. Interestingly, EFS was higher than expected in both arms, with 2.5 years in arm A and arm B compared with the expected 1.98 versus 1.29 years, respectively. Also the 5-year OS is high in both arms, overlapping to that of some Western adjuvant trials [10, 21, 22] and better than that of other neoadjuvant chemotherapy trials in RGC, including MAGIC, FFCD, and EORTC [14, 15, 23] . The homogeneous D2 surgery and the strict study screening probably played a role. The follow-up allowed observing a difference at 10 years, although not statistically significant, in favour of neoadjuvant TCF for both EFS and OS. These results and the interesting percentage of pCRs and pPRs obtained in the preoperative arm lead to suppose that TCF is an effective neoadjuvant chemotherapy for locally advanced RGC. Others reported that patients achieving a pCR tend to live longer than those achieving less in RGC [24] . Probably early stop and consequent underpower could have influenced that, rather than adjuvant treatment arm, considering that around one-third of the patients did not receive any adjuvant chemotherapy and only one-third received all four cycles. A recent meta-analysis, including 12 randomized clinical trials with 1755 patients, reported that neoadjuvant chemotherapy for locally advanced RGC is effective, significantly improving OS, and 5-year survival rate (from 30% to 42%) [25] . However, heterogeneity of the design of the included trials did not clarify the role of adjuvant chemotherapy and, furthermore, the optimal neoadjuvant regimen remains to be determined. It is possible that TCF could be more adequate than ECF in neoadjuvant setting considering our previous observation that the time to response with TCF was half than that required by ECF in a three-arm randomized phase II trial comparing TCF and TC with ECF in advanced disease [19] .
The results of our trial show that TCF can be delivered with higher dose intensity and better feasibility in preoperative than postoperative setting. This confirms previous observation from other trials that used intensive adjuvant chemotherapy in RGC, such as the MAGIC trial evaluating perioperative ECF [14] , and the GISCAD, FFCD, and GOIRC trials [9, 10, 21] examining weekly platinum/epirubicin/leucovorin/5-FU (PELF), 5-FU/cisplatin, and three-weekly PELF, respectively. However, our study represents the first comparison between the pre-and postoperative use of the same docetaxel-based regimen in locally advanced RGC. Other taxane-based chemotherapy has been investigated in the adjuvant setting, showing no significant superiority to fluoropyrimidine-based chemotherapy [22, 26] . Even with optimal multidisciplinary collaboration, neoadjuvant clinical trials in locally advanced RGC face a number of challenges. The MAGIC trial lasted 8 years although the staging work-up was easier than in our study and an extension to include lower third oesophageal adenocarcinomas was amended. The better the baseline staging, the lower the accrual due to the higher number of patients detected as metastatic during the screening phase. That was one of the reasons of the early stop of ours and the EORTC trial [23] , unlike MAGIC and FFCD [14, 15] which had a much less intensive screening phase. Others investigated the reasons for slow patient accrual in the FAMTX phase III neoadjuvant trial [27] .
In conclusion, provided the low statistical power due to early stop, our results did not show superiority of neoadjuvant versus adjuvant TCF in RGC, after a very long median follow-up. However, they confirmed activity of TCF in terms of pCRs and data from the phase II part of the phase III FLOT trial [28] are waiting to verify whether pCR rate will translate into a survival advantage.
Finally, new insights about different molecular profile of gastric cancer lead us to think that future advances in neo-/ adjuvant therapy will come from targeted agents and biomarker development.
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